Track newly listed healthcare and biotech companies, their IPO performance, and market focus — all in one place.
| Company | Ticker | IPO Date | Amount Raised | Focus Area | Summary |
|---|---|---|---|---|---|
| Sionna Therapeutics | SION | February 7, 2025 | $219.2M | Cystic fibrosis | Develops drugs for cystic fibrosis that stabilize the CFTR protein, targeting patients who don’t respond to existing therapies. |
| Aardvark Therapeutics | AARD | February 13, 2025 | $94.2M | Metabolic drugs | A biotech developing oral drugs to treat obesity and rare metabolic diseases like Prader-Willi syndrome by targeting hunger signals in the brain. |
| Anbio Biotech | NNNN | February 19, 2025 | $8M | IVD diagnostics | Makes rapid tests for diseases like COVID-19, flu, and RSV. Products are used by clinics, hospitals, and governments, especially across Asia. |
| Wellgistics Health | WGRX | February 21, 2025 | $4M | Pharmacy tech | Provides pharmacy logistics and inventory software, helping independent pharmacies and small providers manage supply chains. |
| Basel Medical Group | BMGL | February 25, 2025 | $8.82M | Surgical clinics | Operates clinics focused on spine and neurosurgery in Southeast Asia. Services target both local patients and medical tourists. |
| OncoNova Bio | ONVB | February 25, 2025 | $250M | Oncology | Developer of targeted small molecules for resistant solid tumors, expanding Phase II trials post-IPO. |
| Advanced Biomed | ADVB | March 6, 2025 | $6.6M | Oncology diagnostics | Builds microfluidic chips for early-stage cancer detection. These are cheap, small, and designed for fast testing without major lab infrastructure. |
| ImmunoNext Inc. | IMNX | March 10, 2025 | $300M | Immuno-oncology | Emerging player in T-cell therapies for difficult-to-treat cancers, using novel bispecific antibodies. |
| NeuroSpark Health | NSPK | April 5, 2025 | $120M | Neurology | Focused on neurodegenerative diseases, advancing a lead compound for ALS and Parkinson’s symptoms. |
| Cuprina Holdings | CUPR | April 11, 2025 | $13.8M | Bio wound-care | Makes wound-care products that use sterile maggots to clean chronic wounds like diabetic foot ulcers. FDA cleared and already in use. |
| CardioNova | CDNV | May 22, 2025 | $200M | Cardiology | Developing RNA-based treatments for heart failure and other chronic cardiovascular conditions. |
| Hinge Health | HNGE | May 22, 2025 | $437.3M | Dimensional therapy | Provides virtual care for joint and back pain using sensors, remote coaches, and a mobile app. It’s a digital alternative to in-person physical therapy. |
| Omada Health | OMDA | June 6, 2025 | ~$150M | Chronic care digital | A digital platform for chronic conditions like diabetes and hypertension. Patients get coaching, devices, and app-based tracking to manage health remotely. |
| Caris Life Sciences | CAI | June 18, 2025 | $494M | Cancer diagnostics | Caris uses AI and molecular profiling (DNA, RNA, protein) to guide cancer treatment decisions. Doctors use it to match patients to targeted therapies. |
| GeneCure Therapeutics | GNCR | January 18, 2025 | $180M | Rare Genetic Diseases | IPO proceeds fund next-gen gene therapies for ultra-rare disorders with no approved treatments. |